Compound ID | 2875

RG6319, GDC-5780

Class: Small molecule antibacterial agent

Agent Type: Synthetic; Small molecule; Direct acting;
Spectrum of activity: Gram-negative
Mechanism of action: LepB inhibitor (arylomycin)
Target Pathogen: Active against Escherichia coli
Description: For complicated urinary tract infections
Institute where first reported: Genentech; Roche
Year first mentioned: 2022
Highest development stage: Phase 1 (ISRCTN16073754)
Development status: Active
External links:
Guide to Pharmacology: pezulepistat
Citation: https://www.nature.com/articles/s41429-023-00629-8

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.